Polymyxin B vs Colistin in Lung Infections
Polymyxin B should be preferred over colistin for lung infections caused by multidrug-resistant Gram-negative bacteria, particularly in patients with impaired renal function, due to its superior pharmacokinetic profile, lower nephrotoxicity, and lack of required dose adjustment in renal impairment.
Key Pharmacological Differences
The fundamental distinction between these agents lies in their formulation and renal handling. Colistin is administered as the inactive prodrug colistimethate sodium (CMS), which requires conversion to active colistin in vivo. This conversion is unpredictable and leads to suboptimal plasma concentrations, particularly in critically ill patients 1. In contrast, polymyxin B is administered as the active drug, providing immediate and predictable antimicrobial activity 1.
Critically, polymyxin B plasma concentrations are not influenced by renal function, while colistin requires complex dose adjustments based on creatinine clearance 1. This makes polymyxin B substantially easier to dose and more reliable in patients with fluctuating renal function—a common scenario in critically ill patients with severe infections.
Nephrotoxicity Profile
Multiple guidelines and recent meta-analyses demonstrate that polymyxin B is associated with lower incidence of renal failure compared to colistin 1. The 2015 ICU Task Force on Acinetobacter baumannii specifically notes that "the incidence of renal failure seems to be lower with polymyxin B than with colistin" 1.
A 2018 prospective study found nephrotoxicity developed in 39.3% of colistin patients versus only 11.8% of polymyxin B patients when both were administered at currently recommended doses 2. The 2026 meta-analysis revealed that comparative nephrotoxicity is critically dependent on colistin formulation, with polymyxin B showing significantly greater nephrotoxicity only when compared to colistin sulphate (not colistimethate sodium) 3.
Important caveat: When colistin is properly dose-adjusted for renal function, some studies show comparable nephrotoxicity rates 4, but the complexity of dose adjustment and risk of dosing errors remains a practical disadvantage.
Lung Penetration Concerns
A critical limitation of colistin is its poor lung penetration. Studies demonstrate that colistin was undetectable in bronchoalveolar lavage (BAL) at 2 hours after CMS infusion in critically ill patients with ventilator-associated pneumonia 1. This pharmacokinetic failure directly compromises efficacy in respiratory infections.
Recommended Dosing Regimens
Polymyxin B (Preferred)
- Loading dose: 2-2.5 mg/kg IV 1
- Maintenance dose: 1.5-3 mg/kg/day divided in 2 doses 1
- Critical advantage: Same dose in patients on continuous renal replacement therapy (CRRT)—no adjustment needed 1
- Alternative: Continuous infusion may be suitable 1
Colistin (If Polymyxin B Unavailable)
- Loading dose: 6-9 million IU (5 mg/kg) 1, 5, 1, 5
- Maintenance dose: 4.5 million IU every 12 hours in patients with CrCl >50 mL/min 1, 5
- Renal adjustment required: Maintenance dose must be individually adjusted: 2.5 mg × (1.5 × CrCl + 30) IV q12h 6, 5
- CRRT: At least 9 million IU/day 1
- Intermittent hemodialysis: 2 million IU every 12 hours with normal loading dose 1
Dosing conversion critical: 1 million IU colistin = 80 mg CMS = 33 mg colistin base activity 7. Dosing errors are common due to multiple reporting methods 1.
Clinical Efficacy Data
The 2015 ICU guidelines cite retrospective studies showing that in carbapenem-resistant A. baumannii VAP, microbiologic cure rates at day 7 were significantly lower in the colistin group, and 30-day mortality was significantly higher compared to polymyxin B 1. While clinical cure rates were similar, the mortality difference favors polymyxin B.
A 2026 meta-analysis found polymyxin B associated with lower all-cause mortality (OR 0.82,95% CI 0.68-0.98) 3, though this should be interpreted cautiously given observational study limitations.
Practical Algorithm for Selection
Choose Polymyxin B if:
- Patient has renal impairment or fluctuating renal function
- Patient is on or likely to require renal replacement therapy
- Lung/respiratory tract infection (better penetration profile)
- Institutional experience with polymyxin B exists
Choose Colistin only if:
- Polymyxin B is unavailable
- Pharmacy/institutional protocols mandate colistin use
- Patient has stable, normal renal function allowing reliable dose calculation
In either case:
- Always use loading doses 1, 5, 1, 5
- Monitor renal function closely (daily creatinine) 5
- Consider combination therapy with carbapenem if MIC ≤8 mg/L for CRE or ≤32 mg/L for CRAB 7
- Therapeutic drug monitoring is recommended when available 7
Special Populations
Patients on CRRT: Polymyxin B is strongly preferred—no dose adjustment needed, while colistin dosing on CRRT remains inconsistent and poorly defined 1.
Elderly or chronic kidney disease: Polymyxin B preferred due to predictable dosing and lower nephrotoxicity risk 5.
Obese patients: Both drugs should be dosed on ideal body weight 8, but polymyxin B's weight-based dosing without renal adjustment is more straightforward.
Common Pitfalls to Avoid
- Failing to give loading doses: Both agents require loading doses even in renal dysfunction 1
- Colistin dosing errors: Multiple unit expressions (IU, mg CMS, mg CBA) cause frequent errors 1, 7
- Inadequate colistin dosing in critically ill: Standard doses often achieve suboptimal concentrations 1
- Assuming equivalent nephrotoxicity: Polymyxin B is less nephrotoxic in most real-world scenarios 1, 2
- Not monitoring renal function daily: Essential for both agents but critical for colistin dose adjustment 5